T-E Meds has developed several ADC and ARC candidates through the proprietary ADC/ARC platforms, all of which target hard-to-treat cancers.
Two leading ADC candidates, TE-1146 and TE-1182, are currently in preclinical development, with IND filings planned sequentially in 2026.
For detailed information, please refer to the relevant pages on the T-E Meds website: TE-1146, TE-1182, and Anti-CA19-9 ARC.
